TODAY’S NEWS
Drug market will top $825B next year (worldwide – that’s 4-6% growth). That’s a lot of pills/needles/whatevers!
FDA panel gives thumbs up Pfizer HIV drug Selzentry for first-line use – Pfizer Inc. announced today that the U.S. Food and Drug Administration’s (FDA) Antiviral Drugs Advisory Committee voted (10 to 4) to recommend the approval of Selzentry® (maraviroc) tablets for use in treatment-naïve adult patients with CCR5-tropic HIV-1 virus as part of combination therapy.…more
MS – get treated EARLY!
Pharma CEOs who make recommendations about health plan for others – perhaps not the kind they enjoy?
RECOMMENDED
Curriculum Design. Impactiviti has partnerships with consultants and companies who can help you create a strategic map for training. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.
PLUS
I’m all for improved patient compliance. But this and this kinda give me the creeps. Not sure I want that kind of technology in my body, giving reports…
JUST FOR FUN
For some Friday eye candy – 50 beautifully delicious coffee designs.
Coming up this month:
Oct. 19-21 – eXL’s Digital Pharma conference, Bridgewater, NJ. This event will be quite progressive, with more of an informal “unconference” format to maximize interaction. I’ll be co-leading a pre-conference workshop on the 19th on social media, and live-blogging/Twittering. Here’s a discount code for 15% your registration: P615WOO
———-
Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)
Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)
Connect with Steve Woodruff
Leave a Reply